{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
How has been the historical performance of Medico Remedies?
Medico Remedies has shown consistent growth in net sales and profits, with net sales increasing from 121.02 Cr in Mar'22 to 150.94 Cr in Mar'25, and operating profit rising from 7.21 Cr to 15.00 Cr during the same period. The company's total assets also expanded significantly, reflecting a robust financial performance.
Medico Remedies Sees Revision in Market Evaluation Amidst Mixed Financial Signals
Medico Remedies, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting a nuanced shift in its financial and technical outlook. This adjustment follows a detailed reassessment of the company’s quality, valuation, financial trends, and technical indicators, offering investors a refreshed perspective on its market position.
Medico Remedies Forms Golden Cross, Signalling Potential Bullish Breakout
Medico Remedies, a player in the Pharmaceuticals & Biotechnology sector, has recently formed a Golden Cross, a significant technical indicator where the 50-day moving average crosses above the 200-day moving average. This development often signals a potential shift towards a bullish trend and long-term momentum in the stock’s price movement.
Is Medico Remedies overvalued or undervalued?
As of November 27, 2025, Medico Remedies is considered overvalued with a PE ratio of 37.29, a Price to Book Value of 6.33, and an EV to EBITDA of 28.31, indicating high valuations relative to earnings and assets, despite having a lower PE than Sun Pharma and a higher PEG ratio of 0.78 compared to its peers.
How has been the historical performance of Medico Remedies?
Medico Remedies has shown consistent growth in net sales and profits, with net sales increasing from 97.69 Cr in Mar'19 to 150.94 Cr in Mar'25, and profit after tax rising to 10.09 Cr in Mar'25. The company has also improved its operating profit and cash flow, indicating enhanced operational efficiency.
Medico Remedies Shows Strong Financial Growth Amidst Stakeholder Confidence Concerns
Medico Remedies, a microcap in the Pharmaceuticals & Biotechnology sector, has recently adjusted its evaluation, indicating a shift in market sentiment. The company reported strong financial metrics, including a low Debt to EBITDA ratio and significant growth in operating profit and net sales, despite facing some challenges with promoter confidence.
How has been the historical performance of Medico Remedies?
Medico Remedies has shown consistent growth in net sales and profitability, with net sales increasing from 97.69 Cr in Mar'19 to 150.94 Cr in Mar'25, and profit after tax rising from 1.57 Cr to 10.09 Cr during the same period, reflecting improved operational efficiency and a growing profitability margin. Total assets also expanded significantly, indicating a robust financial trajectory.
Why is Medico Remedies falling/rising?
As of 10-Nov, Medico Remedies Ltd's stock price is Rs 51.50, up 3.1% today, reversing a two-day decline. Despite recent gains, the stock has underperformed over the past year, raising concerns about its valuation and future prospects.
When is the next results date for Medico Remedies?
The next results date for Medico Remedies is 13 November 2025.
Medico Remedies Faces Mixed Performance Amid Profit Growth and Stake Reduction Concerns
Medico Remedies, a microcap in the Pharmaceuticals & Biotechnology sector, has seen a recent adjustment in its evaluation score, reflecting a shift in technical trends. Despite a negative return over the past year, the company reported a significant profit increase and maintains a strong capacity to service its debt.
How has been the historical performance of Medico Remedies?
Medico Remedies has shown consistent growth in net sales and profits, with net sales increasing from 121.02 Cr in March 2022 to 150.94 Cr in March 2025, and profit after tax reaching 10.09 Cr. The company also reported improved operating profit and a strengthening balance sheet, indicating a robust performance trajectory.
Medico Remedies Adjusts Evaluation Amid Mixed Performance Indicators and Stakeholder Confidence Shift
Medico Remedies, a microcap in the Pharmaceuticals & Biotechnology sector, has recently adjusted its evaluation, indicating a shift in market sentiment. The company has shown strong financial performance, with significant growth in net sales and operating profit, despite a slight decline in promoter confidence.
How has been the historical performance of Medico Remedies?
Medico Remedies has shown consistent growth in net sales and profitability, with net sales increasing from 97.69 Cr in Mar'19 to 150.94 Cr in Mar'25, and profit after tax rising from 1.57 Cr to 10.09 Cr during the same period, indicating strong operational efficiency and financial performance. Total assets and liabilities have also expanded proportionally, reflecting overall positive financial trends.
Medico Remedies Ltd Faces Selling Pressure with 6.13% Weekly Decline Amid Ongoing Losses
Medico Remedies Ltd is experiencing notable selling pressure, with the stock declining 1.29% today and 6.13% over the past week. Year-to-date, it is down 13.83%, contrasting with the Sensex's gains. Despite a recent monthly increase, the company's long-term performance remains concerning compared to broader market trends.
Why is Medico Remedies falling/rising?
As of 16-Oct, Medico Remedies Ltd's stock price is declining at 48.46, down 1.28%, and has underperformed its sector and the broader market. Despite a 24.70% increase over the past month, it has a year-to-date decline of 10.97%, indicating weak market sentiment.
Medico Remedies Ltd Faces Selling Pressure with 1.66% Decline Amid 7.21% Weekly Loss
Medico Remedies Ltd is experiencing notable selling pressure, with consecutive losses and a significant decline over the past week. While the stock has shown some gains in the past month, it has struggled year-to-date. Its performance over three years has been strong, but stagnation is evident over longer periods.
Medico Remedies Faces Evaluation Shift Amidst Mixed Financial Performance and Stakeholder Concerns
Medico Remedies, a microcap in the Pharmaceuticals & Biotechnology sector, has recently adjusted its evaluation, indicating a shift in market sentiment. Despite a strong Q1 FY25-26 performance with a profit increase, the company faces challenges, including reduced promoter confidence and high valuation metrics.
How has been the historical performance of Medico Remedies?
Medico Remedies has exhibited consistent growth in net sales and profits, with net sales increasing from 97.69 Cr in Mar'19 to 150.94 Cr in Mar'25, and profit after tax rising from 1.57 Cr to 10.09 Cr in the same period. The company's total assets and liabilities also grew significantly, reflecting a strong financial position.
Why is Medico Remedies falling/rising?
As of 09-Oct, Medico Remedies Ltd is currently priced at 51.30, reflecting a 1.08% increase, but has seen a significant drop in investor participation with an 88.94% decline in delivery volume. Despite outperforming the Sensex in the short and medium term, the stock's year-to-date decline of 5.75% raises concerns about its long-term momentum.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
